chevron_left
Drugs to Watch: Innovations driving better solid tumor outcomes in women’s health
Speakers
Historically, women have been underrepresented in research, with female-specific diseases often insufficiently studied or funded—contributing to persistent gaps in diagnosis, treatment, and outcomes. Ovarian cancer still sees late diagnosis and poor survival rates, breast cancer continues to face unmet needs in hard-to-treat subtypes, and women with bladder cancer experience worse outcomes than men.
Using selected Drugs to Watch as case studies, we examine therapies with the potential to reshape treatment approaches and improve patient outcomes across women’s cancers:
- Gedatolisib – a PI3K/mTOR inhibitor in development for breast cancer
- INLEXZO (TAR-200) – a novel intravesical delivery system for gemcitabine in bladder cancer
- Relacorilant – a selective glucocorticoid receptor antagonist for ovarian cancer
What you’ll gain
- Insight into the clinical data behind these emerging therapies
- Understanding of how they differentiate from current standards of care
- Perspective on the unmet needs they aim to address across women’s cancers
- Key considerations for achieving long-term clinical adoption and commercial success
